A recent study published in Nature Communications by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators evaluated a replicating RNA (repRNA) vaccine ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

made up of RNA molecules. But the challenge ... Single Mutation in H5N1 Influenza Surface Protein Could Enable Easier Human Infection Dec. 6, 2024 — A single modification in the protein found on ...

The Trump administration would do well to follow the lead of Maryland, which is taking decisive action to stop the spread of ...

also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H SAN DIEGO, January 06, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ...

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new ...

Scientists have uncovered a blood-based molecular signature that can predict vaccine durability. Could this change ...

The money "allows Moderna to accelerate development of an H5N1 mRNA influenza vaccine that ... and public laboratories to develop messenger RNA (mRNA) vaccines against emerging bio-threats.

As cases of seasonal influenza surge, health officials are closely monitoring a growing threat—the potential fusion of human and bird flu strains.